Talecris Biotherapeutics

Talecris Biotherapeutics receives EU orphan drug designation for Plasmin

Friday, March 11, 2011

Talecris Biotherapeutics has been granted orphan drug designation by the European Commission for the development of Plasmin (human) to treat acute peripheral arterial occlusion (aPAO). Talecris is currently investigating Plasmin in a phase II clinical trial designed to assess its ability to treat aPAO, a condition in which arterial blood flow to the extremities, usually the legs, is blocked by a clot. 

[Read More]